RTP Mobile Logo
Lung Cancer Update, Issue 2, 2011
Released July 2011

Featuring interviews with Drs Chandra P Belani, Harvey I Pass, Gregory J Riely and Everett E Vokes. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85 percent of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Identify distinct subtypes of adenocarcinoma of the lung, including those with EGFR mutations and EML4-ALK gene fusions, and the investigational and approved treatment options for patients with these biomarkers.
    • Describe emerging efficacy and safety data on irreversible EGFR tyrosine kinase inhibitors, and identify patients who might benefit from participation in clinical trials evaluating these novel agents.
    • Apply the results of recent clinical research to the rational selection of EGFR- or VEGF-inhibiting agents for patients with metastatic non-small cell lung cancer (NSCLC).
    • Formulate individualized treatment plans addressing first-line therapy for recurrent or progressive NSCLC, considering unique patient and tumor characteristics.
    • Identify patients with metastatic NSCLC who may benefit from individualized maintenance treatment approaches after successful completion of first-line systemic therapy.
    • Effectively utilize tumor histology and biomarkers in making evidence-based lung cancer treatment decisions.

     

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BelaniAdvisory Committee: Genentech BioOncology, Lilly USA LLC, Pfizer Inc; Consulting Agreements: Genentech BioOncology, Lilly USA LLC. Dr Pass Paid Research: Pfizer Inc. Dr RielyConsulting Agreements: ARIAD Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Tragara Pharmaceuticals Inc; Paid Research: Infinity Pharmaceuticals Inc, Merck and Company Inc, Pfizer Inc; Paid Travel: Bristol-Myers Squibb Company, Pfizer Inc. Dr VokesAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, OSI Oncology, Pfizer Inc; Data and Safety Monitoring Board: Amgen Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
     
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, Genentech BioOncology & OSI Oncology and Lilly USA LLC.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2011
    Expiration date: July 2012

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 2, 2011
Released July 2011

Featuring interviews with Drs Chandra P Belani, Harvey I Pass, Gregory J Riely and Everett E Vokes. (Text and Audio Content)

Read print: